Participation in the 16th International congress on systemic lupus erythematosus (LUPUS 2025)
https://doi.org/10.47360/1995-4484-2025-532-538
Abstract
The LUPUS 2025 Congress showcased cutting-edge data on systemic lupus erythematosus (SLE). Highlights included an updated step-wise treatment algorithm for cutaneous lupus, the proposal of an early triple-therapy regimen for lupus nephritis with standardized histologic response criteria, and the identification of novel biomarkers that enhance patient stratification. In addition, an expert consensus provided therapeutic guidance for 24 rare SLE manifestations.
About the Author
A. A. Shumilova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
Anastasiia A. Shumilova
115522, Moscow, Kashirskoye Highway, 34A
Competing Interests:
None
References
1. Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi: 10.1136/ard-2023-224762
2. Rüegg L, Pluma A, Hamroun S, Cecchi I, Perez-Garcia LF, Anderson PO, et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. 2025;84(6):910-926. doi: 10.1016/j.ard.2025.02.023
3. Khosravi-Hafshejani T, On A, Ali H, Chambers S, Yang X, Almeida Gomes LL, et al. The patterns of recurrence in cutaneous lupus erythematosus: A retrospective analysis of SCLE and DLE flares. J Am Acad Dermatol. 2025;93(4):1125-1126. doi: 10.1016/j.jaad.2025.06.025
4. Furie R, Werth VP, Milliman E, Ferber K, Brown R, Zoghbi J, et al. Pharmacodynamic effects of litifilimab in lupus in the LILAC phase II study: Rapid and sustained reductions in type I interferon-associated gene expression and cytokines. Arthrit Rheumatol. 2025 Jun 9. doi: 10.1002/art.43271
5. Pearson D, Morand E, Wenzel J, Furie R, Dall’Era M, SanchezGuerrero J, et al. Randomized, placebo-controlled phase II study of enpatoran, a small molecule Toll-like receptor 7/8 inhibitor, in cutaneous lupus erythematosus: Results from cohort A. J Rheumatol. 2025;52(Suppl 1):11.1-11. doi: 10.3899/jrheum.2025-0390.O010
6. McDonald KA, Lytvyn Y, Mufti A, Chan AW, Rosen CF. Review on photoprotection: A clinician’s guide to the ingredients, characteristics, adverse effects, and disease-specific benefits of chemical and physical sunscreen compounds. Arch Dermatol Res. 2022;315(4):735-749. doi: 10.1007/s00403-022-02483-4
7. Sammaritano LR, Askanase A, Bermas BL, Dall’Era M, DuarteGarcía A, Hiraki LT, et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthrit Rheumatol. 2025;77(9):1115-1135. doi: 10.1002/art.43212
8. Rovin BH, Ayoub IM, Chan TM, Liu ZH, Mejía-Vilet JM, Floege J. KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney Int. 2024;105(1):S1-69. doi: 10.1016/j.kint.2023.09.002
9. Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, RomeroDiaz J, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 2021; 397(10289):2070-2080. doi: 10.1016/S0140-6736(21)00578-X
10. Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117-1128. doi: 10.1056/NEJMoa2001180
11. Furie RA, Rovin BH, Garg JP, Santiago MB, Aroca-Martínez G, Zuta Santillán AE, et al. Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med. 2025;392(15):1471-1483. doi: 10.1056/NEJMoa2410965
12. Rossi GM, Vaglio A. New treatment regimens, new drugs, and new treatment goals for lupus nephritis. J Clin Med. 2025;14(2):584. doi: 10.3390/jcm14020584
13. Parodis I, Cetrez N, Palazzo L, Alberton V, Anders HJ, Bajema IM, et al. Lupus nephritis trials network (LNTN) repeat kidney biopsy-based definitions of treatment response: A systematic literature review-based proposal. Autoimmun Rev. 2025;24(7):103810. doi: 10.1016/j.autrev.2025.103810
14. Burns G, Legge A. Developing and evaluating a laboratory-based frailty index (FI-LAB) for the prediction of long-term health outcomes in systemic lupus erythematosus. J Rheumatol. 2025;52(Suppl 1):13-14. doi: 10.3899/jrheum.2025-0390.O013
15. Pasternak E, Freud T, Press Y. Association between the frailty index based on laboratory tests and all-cause mortality in hospitalized older adults: Retrospective cohort study. JMIR Aging. 2025;8:e70204. doi: 10.2196/70204
16. Chan EKL, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W, Francescantonio PLC, et al. Report of the First International Consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014–2015. Front Immunol. 2015;6:412. doi: 10.3389/fimmu.2015.00412
17. Nosal RS, Superville SS, Amraei R, Varacallo MA. Biochemistry, antinuclear antibodies (ANA). 2022 Dec 29. Treasure Island (FL):StatPearls Publishing;2025.
18. Tešija Kuna A, Đerek L, Drvar V, Kozmar A, Gugo K. Assessment of antinuclear antibodies (ANA): National recommendations on behalf of the Croatian society of medical biochemistry and laboratory medicine. Biochem Med (Zagreb). 2021;31(2):210-229. doi: 10.11613/BM.2021.020502
19. Fritzler MJ, Choi MY. Antinuclear antibody testing: Gold standard revisited. J Appl Lab Med. 2022;7(1):357-361. doi: 10.1093/jalm/jfab129
20. Zhan K, Buhler KA, Chen IY, Fritzler MJ, Choi MY. Systemic lupus in the era of machine learning medicine. Lupus Sci Med. 2024;11(1):e001140. doi: 10.1136/lupus-2023-001140
21. Moghaddam F, Sajadi J, Clarke A, Bernatsky S, Costenbader K, Chen I, et al. Rheumatology diagnostics utilizing artificial intelligence for ANA pattern identification and titre quantification. J Rheumatol. 2025;52(Suppl 1):71.2-72. doi: 10.3899/jrheum.2025-0390.PT012
22. Raeber ME, Caspar DP, Zurbuchen Y, Guo N, Schmid J, Michler J, et al. Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics. Immunity. 2024;57(9):2232-2250.e10. doi: 10.1016/j.immuni.2024.07.016
23. Smith J, Whittall-Garcia L, Bonilla D, Li Q, Wither J, Gladman DD, et al. Type I interferon status and clinical manifestations in a large cohort of patients with systemic lupus erythematosus. J Rheumatol. 2025;52(Suppl 1):99.1-99. doi: 10.3899/jrheum.2025-0390.PV036
24. Panafidina T, Popkova T, Shumilova A, Gorbunova Y, Kondrateva L, Tchetina E, et al. Effect of comorbidity and standard therapy on interferon status in patients with systemic lupus erythematosus. J Rheumatol. 2025;52(Suppl 1):98.2-99. doi: 10.3899/jrheum.2025-0390.PV035
25. Panafidina T, Popkova T, Shumilova A, Gorbunova Y, Kondrateva L, Tchetina E, et al. Clinical significance of interferon status in patients with systemic lupus erythematosus: Preliminary data. J Rheumatol. 2025;52(Suppl 1):202.1-202. doi: 10.3899/jrheum.2025-0390.PV196
26. Costa R, Guaraná W, Júnior B, Clementino J, Da Costa Neto J, Inês L, et al. Does SLEDAI-2K reflect the interferon-alpha gene signature in systemic lupus erythematosus? Preliminary results from a cohort. J Rheumatol. 2025;52(Suppl 1):139.1-139. doi: 10.3899/jrheum.2025-0390.PV103
27. Costa R, Guaraná W, Júnior B, Pedroza L, Inês L, Sandrin-Garcia P, et al. Ophthalmic involvement in systemic lupus erythematosus is associated with interferon-alpha gene signature: A cross-sectional study. J Rheumatol. 2025;52(Suppl 1):138.2-138. doi: 10.3899/jrheum.2025-0390.PV102
28. Liu Y, Li M, Zhang H, Yin Z, Wang X. Clinical significance of serum soluble scavenger receptor CD163 in patients with lupus nephritis. Lupus. 2024;33(12):1279-1288. doi: 10.1177/09612033241276033
29. Li M, Barreth N, Cheema K, Muruve D, Pierre Y St., Clarke A, et al. Novel urinary biomarker model for differentiating lupus nephritis from ANCA-associated vasculitis. J Rheumatol. 2025;52(Suppl 1):151.2-152. doi: 10.3899/jrheum.2025-0390.PV126
30. Lindblom J, Beretta L, Borghi MO, Alarcón-Riquelme ME, Parodis I. Serum profiling identifies CCL8, CXCL13, and IL-1RA as markers of active disease in patients with systemic lupus erythematosus. Front Immunol. 2023;14:1257085. doi: 10.3389/fimmu.2023.1257085
31. Parodis I, Lagutkin D, Lindblom J, Idborg H, Beretta L, Borghi MO, et al. New IgG and IgA autoantibody specificities against DNA-binding and RNA-binding proteins discriminate systemic lupus erythematosus from health and non-lupus autoimmunity – could anti-LIN28A enhance precision in diagnostics? Ann Rheum Dis. 2025;84(7):1180-1194. doi: 10.1016/j.ard.2025.04.003
32. Arnold J, Carter LM, Md Yusof MY, Dutton K, Wigston Z, Dass S, et al. ANA-associated arthritis: Clinical and biomarker characterization of a population for basket trials. Rheumatology. 2024;63(11):3135-3145. doi: 10.1093/rheumatology/keae269
33. Arnold J, Carter LM, Yusof MYM, Wigston Z, Dominguez DT, Barturen G, et al. Discovery and validation of a new classification of ANA-RMDS that better predict long-term outcomes compared to legacy diagnoses. J Rheumatol. 2025;52(Suppl 1):15-16. doi: 10.3899/jrheum.2025-0390.O015
34. Arnaud L, Ruiz-Irastorza G, Aranow C, Bernatsky S, Dall’Era M, Adelowo O, et al. ERN ReCONNET–SLICC–SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations. Lancet Rheumatol. 2025;7(7):e505-e518. doi: 10.1016/S2665-9913(25)00063-3
35. Branch DW, Kim MY, Guerra MM, Worden J, Laskin CA, DeSancho MT, et al. Certolizumab pegol to prevent adverse pregnancy outcomes in patients with antiphospholipid syndrome and lupus anticoagulant (IMPACT): Results of a prospective, single-arm, open-label, phase 2 trial. Ann Rheum Dis. 2025;84(6):1011-1022. doi: 10.1016/j.ard.2025.02.012
Review
For citations:
Shumilova A.A. Participation in the 16th International congress on systemic lupus erythematosus (LUPUS 2025). Rheumatology Science and Practice. 2025;63(5):532-538. (In Russ.) https://doi.org/10.47360/1995-4484-2025-532-538
Views:
10
Email this article 